

## References

1. Özdamar İ, Özdamar EN. Drug utilization pattern and rational drug use at orthopedics and traumatology outpatient clinics: A cross-sectional study. *Jt Dis Relat Surg*
2. Yimer YS, Addis GT, Alemu MA. Evaluation of prescription completeness, rational drug-use patterns using WHO prescribing, patient-care and facility indicators in Debre Tabor Comprehensive Specialized Hospital, Ethiopia: A cross-sectional study. 22 Jan
3. Wendie TF, Ahmed A, Mohammed SA. Drug use pattern using WHO core drug use indicators in public health centers of Dessie, North-East Ethiopia. 2021 Dec 1;21(1):1–10. Available from: <https://bmcmidinformeddecision.biomedcentral.com/articles/10.1186/s12911-021-01530-w>
4. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. 2018 Sep 3;2018(9). Available from: </pmc/articles/PMC6513645/>
5. Rasmussen L, Wettermark B, Steinke D, Pottegård A. Core concepts in pharmacoepidemiology: Measures of drug utilization based on individual-level drug dispensing data. *Pharmacoepidemiol Drug Saf*. 2022 Oct 1;31(10):1015–26.
6. Park J, Look KA. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization. *Health Serv Res*. 2022 Feb 1;57(1):56–65.
7. Wettermark B, Elseviers M, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al. Introduction to drug utilization research. 2016 Apr 8;1–12. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/9781118949740.ch1>
8. Jacob P, Balasubramanian A, Ramalingam K. A review on steps involved in drug utilization review. *International Journal of Research in Pharmaceutical Sciences*. 118  
  
2020 Jul 9;11(3):4095–8. Available from: [https://www.researchgate.net/publication/343192793\\_A\\_review\\_on\\_steps\\_involved\\_in\\_drug\\_utilization\\_review](https://www.researchgate.net/publication/343192793_A_review_on_steps_involved_in_drug_utilization_review)
9. NCI Dictionary of Cancer Terms - NCI. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms>
10. Madia F, Worth A, Whelan M, Corvi R. Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment. *Environ Int*. 2019 Jul 1;128:417–29.
11. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021 May;71 (3):209–49. Available from: <http://pressroom.cancer.org/GlobalCancerStats2020>
12. Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective - Patricia Piña-Sánchez, Antonieta Chávez-González, Martha Ruiz-Tachiquín, Eduardo Vadillo, Alberto Monroy-García, Juan José Montesinos, Rocío Grajales, Marcos Gutiérrez de la Barrera, Hector Mayani, 2021 Available from: <https://journals.sagepub.com/doi/full/10.1177/10732748211038735>
13. Ali D, Naqvi SBS, Nasiri MI, Ahmed K, Zaheer K, Azeem M, et al. Evaluation of prevalence of different types of cancer and its chemotherapy in various ethnic groups of Pakistan: A retrospective

study. *Brazilian Journal of Pharmaceutical Sciences*. 2020;56:1–8. Available from: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1984-82502020000100651&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100651&tlng=en)

14. Qureshi MA, Khan S, Sharafat S, Quraishy MS. Common cancers in Karachi, Pakistan: 2010-2019 cancer data from the dow cancer registry. *Pak J Med Sci*. 2020 Nov 1;36(7):1572–8. 119

15. Pervez S, Jabbar AA, Haider G, Ashraf S, Qureshi MA, Lateef F, et al. Karachi Cancer Registry (KCR): Age-Standardized Incidence Rate by Age-Group and Gender in a Mega City of Pakistan. *Asian Pacific Journal of Cancer Prevention*. 2020;21(11):3251–8.

16. 586-Fact sheet. Pakistan.

17. Rehman SH, Majid B, Syed SA, Qureshi MA. Quantitative Analyses of Skin Cancer Research in Pakistan. *Pak J Med Sci*. 2021 Mar 1;37(2):582–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33679954>

18. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA Oncol*. 2017 Apr 1;3(4):524–48.

19. Pellino A, Riello E, Nappo F, Brignola S, Murgioni S, Djaballah SA, et al. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. 2019 Oct 10;25(38):5773. Available from: [/pmc/articles/PMC6801189/](https://pubmed.ncbi.nlm.nih.gov/31801189/)

20. Frey S, Blankart CR, Stargardt T. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. *Pharmacoeconomics*. 2016 May 1;34(5):479–98.

21. Boslaugh S. Cancer. *Encyclopedia of Epidemiology*. 2012 Oct 5;

22. Colditz GA. The SAGE Encyclopedia of Cancer and Society. The SAGE Encyclopedia of Cancer and Society. 2015 Aug 31;

23. Colditz G. Future of Cancer. *Encyclopedia of Cancer and Society*. 2014 Jan 16; 120

24. Bhakta N, Force LM, Allemani C, Atun R, Bray F, Coleman MP, et al. Childhood cancer burden: a review of global estimates. *Lancet Oncol*. 2019 Jan 1;20(1):e42–53.

25. Guide to Cancer Early Diagnosis. 2017; Available from: <http://apps.who.int/bookorders>.

26. Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. *Front Mol Biosci*. 2018 Aug 27;5(AUG):76.

27. Siddiqua A. Drug Utilization Evaluation of Anti Cancer Drugs. 2014;4(May).

28. What Is Cancer? – NCI. Available from: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>

29. Biersack B. Alkylating anticancer agents and their relations to microRNAs. *Cancer Drug Resistance*;2(1):1. Available from: [/pmc/articles/PMC9019174/](https://pubmed.ncbi.nlm.nih.gov/31801174/)

30. alkylating agent | chemical compound | Britannica. Available from: <https://www.britannica.com/science/alkylating-agent>

31. Alkylating Agents in Chemotherapy: The Benefits & Limitations. Available from: <https://www.healthline.com/health/alkylating-agents>
32. Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: A double-edged sword. *J Cancer*; 11(17):5135. Available from: [/pmc/articles/PMC7378927/](https://pubmed.ncbi.nlm.nih.gov/37378927/)
33. Antibiotics for cancer treatment: A double-edged sword - PMC. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378927/>
34. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab*. 2016 Jan 12;23(1):27–47. 121
35. Mehrmohamadi M, Jeong SH, Locasale JW. Molecular features that predict the response to antimetabolite chemotherapies. *Cancer & Metabolism* 2017 5:1. 2017 Oct 3;5(1):1–13. Available from: <https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-017-0170-3>
36. Kinjo J, Nakano D, Fujioka T, Okabe H. Screening of promising chemotherapeutic candidates from plants extracts. *J Nat Med* . 2016 Jul 1; 70(3):335–60. Available from: <https://link.springer.com/article/10.1007/s11418-016-0992-2>
37. M. Pereira D, Valentao P, Correia-da-Silva G, Teixeira N, B. Andrade P. Plant Secondary Metabolites in Cancer Chemotherapy: Where are We? *Curr Pharm Biotechnol*. 2012 Mar 14;13(5):632–50.
38. What Are Lung Cancer Chemotherapy Topoisomerase Inhibitors? Available from: <https://lungcancer.net/medications/chemotherapy-irinotecan-etoposide>
39. Liang X, Wu Q, Luan S, Yin Z, He C, Yin L, et al. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. *Eur J Med Chem*. 2019 Jun 1;171:129–68.
40. Dehshahri A, Ashrafizadeh M, Ghasemipour Afshar E, Pardakhty A, Mandegary A, Mohammadinejad R, et al. Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems. *Pharmacol Res*. 2020 Jan 1;151:104551.
41. Targeted Therapy: What It Is, Process & Side Effects Available from: <https://my.clevelandclinic.org/health/treatments/22733-targeted-therapy>
42. Hormonal therapy | Canadian Cancer Society. Available from: <https://cancer.ca/en/treatments/treatment-types/hormone-therapy>
43. Al-Shahri MZ, Abdullah A, Alansari A, Sroor M. Opioid Prescribing Patterns Before and After an Inpatient Palliative Care Consultation. <https://doi.org/10.1177/1122049909119897260>. 2019 Dec 26;37(9):738–42. Available from: <https://journals.sagepub.com/doi/abs/10.1177/1049909119897260>
44. Bepari A, Sakre N, Rahman I, Niazi SK, Dervesh AM. The Assessment of Drug Utilization Study of Anticancer Drugs Using WHO Prescribing Indicators in a Government Tertiary Care Hospital of the Hyderabad - Karnataka Region of India. *Open Access Maced J Med Sci*. 2019 Apr 13;7(7):1203–8. Available from: <https://oamjms.eu/index.php/mjms/article/view/2597>
45. 1., Elahi E Asodshvww to HACS of PakistanJ of PTechnology 2019;35(1):41 42. doi:10.1177/8755122518810853. No Title.

46. Sarwar MR, Iftikhar S, Saqib A. Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and highincome class patients in Pakistan. *BMC Cancer*. 2018 Jan 3;18(1):1–11. Available from: <https://bmc cancer.biomedcentral.com/articles/10.1186/s12885-017-3980-3>
47. Balkhi B, Alqahtani S, Altayyar W, Ghawaa Y, Alqahtani Z, Alsaleh K, et al. Drug utilization and expenditure of anticancer drugs for breast cancer. *Saudi Pharmaceutical Journal*. 2020 Jun 1;28(6):669–74.
48. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. *Ecancermedicalscience*. 2019 Sep 10;13. Available from: <https://pubmed.ncbi.nlm.nih.gov/31537986/>
49. Ang CY, Tan SY, Zhao Y. Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy. *Org Biomol Chem*. 2014 Jun 18;12(27):4776–806. Available from: <https://pubs.rsc.org/en/content/articlehtml/2014/ob/c4ob00164h>
50. Cool L, Vandijck D, Debruyne P, Desmedt M, Lefebvre T, Lycke M, et al. Organization, quality and cost of oncological home-hospitalization: A systematic review. *Crit Rev Oncol Hematol*. 2018 Jun 1;126:145–53. 123
51. Babasahib SK, Maria S, Rawther SCH. Drug Utilization and Cost Analysis Review of Anticancer Drugs Used in a Tertiary Care Teaching Hospital in South India. *J Glob Oncol*. 2018 Oct 28;(4\_suppl\_2):73s–73s. Available from: <http://ascopubs.org/doi/10.1200/jgo.18.43100>
52. M M, Martin PJM, R L, S K, P S, Rajan, et al. Prescribing Pattern of Anticancer Drugs in a Medical Oncology Department of a Tertiary Care Teaching Hospital. *Ann Med Health Sci Res*. 2017; Available from: <https://www.amhsr.org/articles/prescribing-pattern-of-anticancer-drugs-in-a-medicaloncology-department-of-a-tertiary-care-teachinghospital-4090.html>
53. Kulkarni MD, Hussaini SA, Padwal SL, Khandelwal PN, Doifode SM, More PP. Drug utilization review of anticancer drugs in cancer outpatient department of the Government Medical College, Aurangabad. *Int J Basic Clin Pharmacol*. 2017 Jan 27;3(5):879–83. Available from: <https://www.ijbcp.com/index.php/ijbcp/article/view/1121>
54. Pantziarka P, Verbaanderd C, Sukhatme V, Capistrano R, Crispino S, Gyawali B, et al. ReDO\_DB: the repurposing drugs in oncology database. *Ecancermedical science*. 2018 Dec 6;12:1–19. Available from: [https://ecancer.org/journal/12/full/886-redo\\_db-the-repurposing-drugs-in-oncology-database.php](https://ecancer.org/journal/12/full/886-redo_db-the-repurposing-drugs-in-oncology-database.php)
55. Kumar BS. Drug Utilization Review and Cost Analysis of Anticancer Drugs Used in a Tertiary Care Teaching Hospital Available from: [www.ijpsonline.com](http://www.ijpsonline.com)
56. Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. *BMC Syst Biol*. 2017 Oct 3 ;11(5):1–17. Available from: <https://bmcsystbiol.biomedcentral.com/articles/10.1186/s12918-017-0464-7>
57. Mugada V, Paruchuri A, Munagala M. Drug Utilization Evaluation of Anticancer Drugs in a Tertiary Care Teaching Hospital: a Descriptive Observational Study. *J Appl Pharm Sci*. 2016;98–101. Available from: [http://www.japsonline.com/abstract.php?article\\_id=2019124](http://www.japsonline.com/abstract.php?article_id=2019124)

58. Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, et al. Provider and patient burdens of obtaining oral anticancer medications. *Am J Manag Care*. 2018 Apr 4;24(4):e128. Available from: [/pmc/articles/PMC7596764/](https://pubmed.ncbi.nlm.nih.gov/27514312/)
59. Louis DZ, Hegarty SE, Leoni M, de Palma R, Varga S, Melotti R. Variation in hospital utilization at the end of life for patients with cancer in the Emilia-Romagna region of Italy. *Tumori* . 2016 Nov 1; 102(6):614–20. Available from: [https:// pubmed.ncbi.nlm.nih.gov/27514312/](https://pubmed.ncbi.nlm.nih.gov/27514312/)
60. Arshad S, Mahmood S, Rasool S, Hayat S, Zafar S, Zehra T. Rational Drug use in Pakistan : A systematic review. 2016;2(4):116–22.
61. Nishita AA, Rispa D, Harshini Y R, R S. Drug Utilization Evaluation and Cost Analysis of Antiemetic Drugs Prescribed in Oncology Ward In a Quaternary Care Hospital. *Asian Journal of Pharmaceutical and Clinical Research* . 2016 Sep 1 ;9(5):97. Available from: <http://www.innovareacademics.in/journals/index.php/ajpcr/article/view/12464>
62. Patel H, Parthasarathi G, Madhan R. Utilization Evaluation of Anti-Cancer Drugs as Adjuvant and Neo-Adjuvant Therapy in the Management of Breast Cancer in a Developing Country. *Value in Health*. 2016 May;19(3):A171. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1098301516016120>
63. Pentareddy MR, AVSS, DS, YS, GP, DTVN, et al. Prescription Pattern of Anticancer Drugs in a Tertiary Care Hospital. *Journal of Evidence Based Medicine and Healthcare*. 2015 May;2(20):3001–9. Available from: [http://www.jebmh.com/ data\\_pdf/1\\_Rohini.pdf](http://www.jebmh.com/data_pdf/1_Rohini.pdf)
64. Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, et al. Hurdles and delays in access to anti-cancer drugs in Europe. Available from: [www.ecancer.org](http://www.ecancer.org) 125
65. Mori J, Tanimoto T, Miura Y, Kami M. Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan. *Jpn J Clin Oncol* . 2015 Mar;45(6):588–94. Available from: <https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyv030>
66. Miyamoto S, Yamada M, Kasai Y, Miyauchi A, Andoh K. Anticancer drugs during pregnancy . Vol. 46, *Japanese Journal of Clinical Oncology*. Oxford University Press; 2016. p. 795–804. Available from: <https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyw073>
67. Builders M, Ogbole E, Akande T, Ogundeko T. Drug Utilization Study in Bingham University Teaching Hospital. *Donnish Journal of Medicine and Medical Sciences* . 2015 Jun 11 [cited 2022 Nov 7];2(5):72–7. Available from: <http://donnishjournals.org/djmms/abstract/2015/june/Builders-et-al.php>
68. Aggarwal M, Chawla S, Singh K. Prescribing pattern of anticancer drugs among inpatients in a tertiary care hospital. *Indian J Pharmacol*. 2014;
69. Hin CM, Hong CC. Oncology Pharmacist’s Role and Impact on the Multidisciplinary Patient-Centre Practice of Oncology Clinic in Public Hospitals. *Asia Pacific Journal of Health Management* . 2019 Apr 15 [cited 2022 Nov 7];14 (1): 16–16. Available from: <https://journal.achsm.org.au/index.php/achsm/article/view/203>
70. Goel A. A randomized double blind study evaluating efficacy, safety and immunogenicity of ABP 798 compared with Retuximab in subjects with CD20 positive B-Cell NHL. View project. 2014; Available from: <http://www.cibtech.org/jms.htm>

71. Takizawa O, Urushihara H, Tanaka S, Kawakami K. Utilization trend and management of oral anticancer medicines using nationwide pharmacy database and questionnaire survey at pharmacies in Japan. *Pharmacoepidemiol Drug Saf.* 2014; 126

72. Jiang Y, Lin W, Zhu L. Targeted Drug Delivery for the Treatment of Blood Cancers. *Molecules.* 2022;27(4):1–16.

73. Niki Carver<sup>1</sup>; Zohaib Jamal<sup>2</sup>; Allison M. Dering Anderson<sup>3</sup>. Drug Utilization Review - PubMed . In: StatPearls . Treasure Island (FL): StatPearls Publishing; 2022 Jan. 2021 . Available from: <https://pubmed.ncbi.nlm.nih.gov/28722899/>

74. Chowdhury TP, Starr R, Brennan M, Knee A, Ehresman M, Velayutham L, et al. A quality improvement initiative to improve medication management in an acute care for elders program through integration of a clinical pharmacist. *J Pharm Pract.* 2018 Feb 1;33(1):55–62.

75. Zhang Y, Wushouer H, Han S, Fu M, Guan X, Shi L, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. *BMJ Glob Health.* 2021 Jul 1; 6(7):e006196. Available from: <https://gh.bmj.com/content/6/7/e006196>

76. Faley B, Fanikos J. Best Practices for Medication Utilization Evaluations in Postsurgical Pain Management. *Curr Emerg Hosp Med Rep.* 2017 Mar ; 5(1):33–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28413718>

77. Bossaer JB, Eskens D, Gardner A. Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics. <https://doi.org/10.1177/1078155220984244> . 2021 Jan 12; 28(1):82–6. Available from: <https://journals.sagepub.com/doi/abs/10.1177/1078155220984244>

78. Negri E, Rossi M, Bonifazi M, Franchi M, Carioli G, Zocchetti C, et al. Clinical use, safety and effectiveness of novel high cost anticancer therapies after marketing approval: a record linkage study. *Epidemiol Biostat Public Health.* 2013 ; 10(3). Available from: <https://riviste.unimi.it/index.php/ebph/article/view/18199>

79. Kadam RL, Motghare VM, Sontakke S, Mahobia V, Diwan AK. Study of prescription pattern and adverse drug reactions of antineoplastic drugs in patients 127

with breast cancer in a tertiary care teaching hospital. *Indian Journal of Pharmacy and Pharmacology.* 4(4):210. Available from: <http://oaji.net/articles/2017/1495-1524563931.pdf>

80. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. *Journal of Clinical Oncology.* 2012 Nov 10;30(32):4017–25.

81. Khaliq SA, Naqvi SB, Fatima A. Retrospective study of cancer types in different ethnic groups and genders at Karachi. *Springerplus.* 2013 Mar 19;2(1):1–6. Available from: <https://springerplus.springeropen.com/articles/10.1186/2193-1801-2-118>

82. Dranitsaris G, Truter I, Lubbe MS, Cottrell W, Spirovski B, Edwards J. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. *J Eval Clin Pract.* 2012 Apr;18(2):343–51.

83. Khan GM, Thapa RK, Adhikari DS, Rajbhandari M. Evaluation of Cancer Prevalence and Cytotoxic Medication Prescribing in Central Region of Nepal. 2013;9(I):189–99.
84. Sahoo AK, Gupta D, Dhaneria S, Thangaraju P, Singh A. Retrospective Analysis of Drug Prescription Statistics in a Tertiary Care Center in India: Recommendations for Promoting Prudent Utilization of Drugs. *J Res Pharm Pract* . 2020; 9(3):146–50. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33489983>
85. Remesh A. Toxicities of anticancer drugs and its management. *Int J Basic Clin Pharmacol* . 2017 Feb 3; 1(1):2–12. Available from: <https://www.ijbcp.com/index.php/ijbcp/article/view/1388>
86. Fernandez MH, Villaverde RM, Yustos MA, Expósito FN, Gonzalez JLL, Infantes MRL, et al. The Off-Label Use of Antineoplastics in Oncology Is Limited But Has 128 Notable Scientific Support in a University Hospital Setting. *Front Pharmacol* . 2019; 10(OCT):1210. Available from: [/pmc/articles/PMC6820060/](https://pmc/articles/PMC6820060/)
87. Seow H, Bainbridge D. A Review of the Essential Components of Quality Palliative Care in the Home. *J Palliat Med* . 2017 Dec 12;20(Suppl 1):S-37. Available from: [/pmc/articles/PMC5733665/](https://pmc/articles/PMC5733665/)
88. Scarborough BM, Smith CB. Optimal Pain Management for Patients with Cancer in the Modern Era. *CA Cancer J Clin* . 2018 May; 68(3):182. Available from: [/pmc/articles/PMC5980731/](https://pmc/articles/PMC5980731/)
89. M M, Martin PJM, R L, S K, P S, Rajan, et al. Prescribing Pattern of Anticancer Drugs in a Medical Oncology Department of a Tertiary Care Teaching Hospital. *Ann Med Health Sci Res*; Available from: <https://www.amhsr.org/articles/prescribing-pattern-of-anticancer-drugs-in-a-medicaloncology-department-of-a-tertiary-care-teachinghospital-4090.html>
90. Zaal RJ, den Haak EW, Andrinopoulou ER, van Gelder T, Vulto AG, van den Bemt PMLA. Physicians' acceptance of pharmacists' interventions in daily hospital practice. *Int J Clin Pharm* . 2020 Feb 1;42(1):141–9. Available from: <https://link.springer.com/article/10.1007/s11096-020-00970-0>
91. Tevfik Dorak M, Karpuzoglu E, Mosher MJ, Rao SMR. Gender differences in cancer susceptibility: an inadequately addressed issue. 2012 ; Available from: [www.frontiersin.org](http://www.frontiersin.org)
92. Mugada V, Paruchuri A, Munagala M. Drug Utilization Evaluation of Anticancer Drugs in a Tertiary Care Teaching Hospital: a Descriptive Observational Study. *J Appl Pharm Sci* 2016;098–101. Available from: [http://www.japsonline.com/abstract.php?article\\_id=2019129](http://www.japsonline.com/abstract.php?article_id=2019129)
93. Islam MM, Iqbal U, Walther BA, Nguyen PA, Li YC (Jack), Dubey NK, et al. Gender-based personalized pharmacotherapy: a systematic review. *Arch Gynecol Obstet*. 2017 Jun 1;295(6):1305–17.
94. Tevfik Dorak M, Karpuzoglu E. Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue. *Front Genet* . 2012 ; 3(NOV):1–11. Available from: [/pmc/articles/PMC3508426/](https://pmc/articles/PMC3508426/)
95. Augustus GJ, Ellis NA. Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. *Am J Pathol* . 2018 Feb 1; 188(2):291. Available from: [/pmc/articles/PMC5785537/](https://pmc/articles/PMC5785537/)
96. Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: Meta-analysis of various published studies to determine variation in cancer figures resulting from marked

population heterogeneity in different parts of the country. *World J Surg Oncol* 2018 Jul 5;16(1):1–11. Available from: <https://wjso.biomedcentral.com/articles/10.1186/s12957-018-1429-z>

97. Kim HI, Lim H, Moon A. Sex differences in cancer: Epidemiology, genetics and therapy. *Biomol Ther (Seoul)*. 2018;26(4):335–42.

98. Pedersen JK, Engholm G, Skytthe A, Christensen K. Cancer and aging: Epidemiology and methodological challenges. *Acta Oncol (Madr)*. 2016;55:7–12.

99. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. *British Journal of Cancer* 2020 122:7 . 2020 Feb 11;122(7):943–52. Available from: <https://www.nature.com/articles/s41416-019-0721-1>

100. Khaliq SA, Naqvi SB, Fatima A. Retrospective study of cancer types in different ethnic groups and genders at Karachi. 2013;2–7. 130

101. Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. *JAMA Oncol*. 2016;2(10):1295–302.

102. American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers – PMC. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940540/>

103. Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. *Journal of Clinical Oncology* . 2014 Mar 3; 32(8):833. Available from: [/pmc/articles/PMC3940540/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940540/)

104. Karachi Cancer Registry Data--implications for the National Cancer Control Program of Pakistan – PubMed. Available from: <https://pubmed.ncbi.nlm.nih.gov/15075010/>

105. D’Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, et al. Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. *JAMA Oncol*. 2017 Feb 1; 3(2):169–77. Available from: <https://jamanetwork.com/journals/jamaoncology/fullarticle/2591158>

106. Khaliq SA. Studies On Epidemiology of Cancer at Studies on Epidemiology of Cancer AT. 2012;1–304.

107. Qureshi MA, Syed SA, Sharafat S. Lip and oral cavity cancers (C00-C06) from a mega city of Pakistan: Ten-year data from the Dow Cancer Registry. *J Taibah Univ Med Sci*. 2021 Aug 1;16(4):624–7.

108. Ali A, Manzoor MF, Ahmad N, Aadil RM, Qin H, Siddique R, et al. The Burden of Cancer, Government Strategic Policies, and Challenges in Pakistan: A Comprehensive Review. *Front Nutr*. 2022 Jul 22;9:1553. 131

109. WHO EMRO | Smokeless tobacco use in Pakistan and its association with oropharyngeal cancer | Volume 16, supplement | EMHJ volume 16, 2010 Available from: <https://www.emro.who.int/emhj-volume-16-2010/volume-16-supplement/article-03.html>

110. Brierley J, Gospodarowicz M, O’Sullivan B. The principles of cancer staging. *Ecanermedicalscience* . 2016; 10. Available from: [/pmc/articles/PMC5215238/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215238/)



111. Rattani SA, Dahlke S, Cameron B. Cancer Care in Pakistan: A Descriptive Case Study. *Research Article Global Qualitative Nursing Research*;9:1–12. Available from: <https://us.sagepub.com/en-us/nam/open-access-at-sage>
112. Seoane J, Takkouche B, Varela-Centelles P, Tomás I, Seoane-Romero JM. Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis. *Clinical Otolaryngology*. 2012; 37(2):99–106. Available from: <https://doi.org/10.1111/j.1749-4486.2012.02464.x>
113. Megan. Cancer Staging: What, Why and How? . Washington University School of Medicine in St. Louis. Available from: <https://surgery.wustl.edu/cancer-staging-what-why-and-how/>
114. Ali D, Naqvi SBS, Nasiri MI, Ahmed K, Zaheer K, Azeem M, et al. Evaluation of prevalence of different types of cancer and its chemotherapy in various ethnic groups of pakistan: A retrospective study. *Brazilian Journal of Pharmaceutical Sciences*. 2020;
115. Steele NP, Wenig BM, Sessions RB. A case of pleomorphic adenoma of the parotid gland metastasizing to a mediastinal lymph node. *Am J Otolaryngol*. 2007 Mar; 28(2):130–3. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17362821>
116. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types Of Gastrointestinal Cancer. *Gastroenterology*. 2020 Jul 1; 159(1):335. Available from: [/pmc/articles/PMC8630546/](https://pubmed.ncbi.nlm.nih.gov/32444446/) 132
117. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Maddalena Laterza M, et al. Treatment of gastric cancer. *World J Gastroenterol* . 2014; 20(7):1635–49.
118. Starzyńska A, Sobocki BK, Alterio D. Current Challenges in Head and Neck Cancer Management. *Cancers (Basel)*. 2022 Jan 1; 14(2). Available from: [/pmc/ articles/PMC8773596/](https://pubmed.ncbi.nlm.nih.gov/36773596/)
119. Begum N. Breast Cancer in Pakistan: A Looming Epidemic. *J Coll Physicians Surg Pak*. 2018 Feb 1; 28(2):87–8.
120. Brown A, Kumar S, Tchounwou PB. Cisplatin-Based Chemotherapy of Human Cancers. *J Cancer Sci Ther*. 2019; 11(4). Available from: [/pmc/articles/ PMC7059781/](https://pubmed.ncbi.nlm.nih.gov/31059781/)
121. Skoetz N, Haque M, Weigl A, Kuhr K, Monsef I, Becker I, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. *Cochrane Database Syst Rev*. 2017 Sep 5; 2017(9). Available from: [/pmc/articles/PMC6483780/](https://pubmed.ncbi.nlm.nih.gov/2803780/)
122. Lavdaniti M, Tsitsis N. Investigation of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy. *Health Psychol Res*. 2014 Nov 11; 2(3):1550. Available from: [/pmc/articles/PMC4768588/](https://pubmed.ncbi.nlm.nih.gov/268588/)
123. Mustian KM, Darling T v, Janelins MC, Jean-Pierre P, Roscoe JA, Morrow GR. Chemotherapy-Induced Nausea and Vomiting. *US Oncology*; 4(1):19–23. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24761161>
124. Vrabel M. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. *Clin J Oncol Nurs*. 2007; 11(6):809–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/18063539/>
125. Innocent M Nyamu DG, Maranga ISO KPN, Innocent M, Karimi PN, Nyamu DG, Maranga ISO. Efficacy and cost of granisetron versus ondansetron in the prevention 133

of chemotherapy induced nausea and vomiting among cancer patients at Kenyatta National Hospital. *Int J Pharm Sci Res.* 2018;9(4):1644–9.

126. Pittayanon R, Piyachaturawat P, Rerknimitr R, Prueksapanich P, Chaitongrat S, Lertsuwunseri V, et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. *J Gastroenterol Hepatol.* 2019 Sep 1; 34(9):1517–22. Available from: <https://pubmed.ncbi.nlm.nih.gov/30919492/>

127. Najafi S, Ansari M, Kaveh V, Haghighat S. Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial. *BMC Cancer.* 2021 Dec 1; 21(1):1–12. Available from: <https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08197-6>

128. Dur W. Drug Utilization Review. 2009;(November).

129. Hennessy S, Soumerai SB, Lipton HL, Strom BL. Drug Utilization Review. In: *Pharmacoepidemiology*. Chichester, UK: John Wiley & Sons, Ltd; 2007. p. 439–53. Available from: <http://doi.wiley.com/10.1002/9780470059876.ch29>

130. Kim HJ, Kim YS, Park SH. Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: A randomized study. *BMC Palliat Care*. 2015 Sep 16; 14(1):1–6. Available from: <https://bmcpalliatcare.biomedcentral.com/articles/10.1186/s12904-015-0038-7>

131. Opioids for Cancer Pain | Treatment and Side Effects. Available from: <https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain/opioid-pain-medicines-for-cancer-pain.html>